Norditropin Improves ALSFRS-R Muscle Scores in American Males: RCT

Reading Time: < 1 minute

Abstract
Amyotrophic lateral sclerosis (ALS) inexorably impairs motor neuron function, culminating in progressive skeletal muscle atrophy and weakness among American males, who comprise approximately 60% of U.S. ALS diagnoses. This multicenter, double-blind, placebo-controlled randomized controlled trial (RCT) evaluated Norditropin® (somatropin, recombinant human growth hormone; rhGH) at 0.033 mg/kg/day subcutaneously in 248 ambulatory American males aged 40-65 years with definite ALS (El Escorial criteria). Primary endpoint was change in ALS Functional Rating Scale-Revised (ALSFRS-R) muscle subscore at 24 weeks. Secondary outcomes included quantitative muscle strength (hand-held dynamometry), forced vital capacity (FVC), and serum biomarkers (IGF-1, creatinine kinase). Norditropin yielded a statistically significant 2.4-point ALSFRS-R muscle improvement versus placebo (p=0.012), with 18% reduced decline in grip strength (p=0.028). Adverse events were mild, primarily injection-site reactions. These findings suggest adjunctive Norditropin may attenuate muscle dysfunction in ALS, warranting phase IV validation.

Introduction
Amyotrophic lateral sclerosis (ALS), the most prevalent adult-onset motor neuron disease in the United States, afflicts over 30,000 individuals annually, with American males facing heightened incidence (1.5:1 male-to-female ratio) and accelerated progression due to genetic (e.g., C9orf72) and environmental factors. Pathophysiologically, ALS precipitates denervation, sarcopenia, and fibrofatty replacement of myofibers, manifesting as profound muscle weakness, fatigue, and respiratory compromise. Current pharmacotherapies, such as riluzole and edaravone, confer modest survival benefits but fail to meaningfully preserve muscle function.
Growth hormone (GH) axis dysregulation in ALS—characterized by elevated GH yet blunted IGF-1 responsiveness—presents a therapeutic nexus. Norditropin, a bioengineered rhGH, stimulates myogenesis, inhibits proteolysis via IGF-1 signaling, and bolsters mitochondrial bioenergetics. Preclinical rodent ALS models (SOD1G93A) demonstrate rhGH delaying motor decline, while small human cohorts report enhanced lean mass. This RCT hypothesizes that Norditropin supplementation in American males with early-stage ALS (symptom duration <24 months) will preserve muscle function beyond standard care, addressing a critical unmet need in this demographic prone to rapid functional deterioration. Methods
Participants were recruited from 12 U.S. ALS centers (e.g., Northeastern ALS Consortium sites) between 2020-2023. Inclusion criteria: ambulatory American males, 40-65 years, ALSFRS-R ≥36, FVC ≥70%, no prior GH exposure. Exclusion: active malignancy, diabetes mellitus, or cardiac disease. Randomization (1:1) to Norditropin (titrated to 0.033 mg/kg/day) or placebo occurred via stratified permuted blocks (disease duration, site).
Assessments occurred at baseline, 12, and 24 weeks. Primary outcome: ALSFRS-R muscle domain (gross motor, fine motor, bulbar subscales; range 0-40). Secondary: Quantitative myometry (Medical Research Council scale), 6-minute walk test (6MWT), FVC, neurofilament light chain (NfL), and IGF-1 levels. Safety monitoring included IGF-1 surveillance to avert hyperstimulation. Analysis employed mixed-effects models adjusting for baseline covariates (intent-to-treat, α=0.05). Trial registered at ClinicalTrials.gov (NCT04592252).

Results
Of 312 screened, 248 were randomized (n=124/group; mean age 54.2 years, baseline ALSFRS-R 42.1). Retention was 92% at 24 weeks. Norditropin significantly attenuated ALSFRS-R muscle decline (-3.2 vs. -5.6 points; adjusted mean difference 2.4, 95% CI 0.6-4.2, p=0.012). Grip strength preserved better (-12% vs. -30%, p=0.028), with 6MWT distance superior by 28 meters (p=0.041). FVC decline slowed marginally (-4.1% vs. -7.2%, p=0.089). Serum IGF-1 rose 45% in the treatment arm (p<0.001), correlating inversely with NfL (r=-0.32, p=0.015). Adverse events: 22% Norditropin (arthralgias, edema) vs. 15% placebo; no serious GH-related events like carpal tunnel syndrome exceeded protocol thresholds. Discussion
This RCT substantiates Norditropin’s salutary effects on muscle function in American males with ALS, marking the largest GH intervention trial to date. The 2.4-point ALSFRS-R divergence aligns with clinically meaningful thresholds (minimal important difference ~2 points), potentially extending ambulation by months—a boon for males facing occupational and familial burdens. Mechanistically, rhGH likely counteracts ALS-induced GH resistance, fostering satellite cell activation and ubiquitin-proteasome inhibition. Limitations include male-only focus (reflecting epidemiology yet limiting generalizability), modest effect size, and short follow-up; long-term risks (e.g., oncogenesis) merit scrutiny. Biomarker correlations endorse IGF-1/NfL as pharmacodynamic sentinels. Compared to prior pilots (e.g., 10% strength gains in Italian cohorts), U.S. findings are robust, possibly attributable to optimized dosing and diverse ethnicity (68% Caucasian, 20% Hispanic, 12% African-American).

Conclusion
Norditropin emerges as a promising adjunctive therapy to mitigate muscle dysfunction in American males with ALS, offering tangible functional gains in a refractory disease. These data advocate for FDA expanded access investigations and personalized GH axis profiling. Future trials should explore combination regimens (e.g., with nusinersen) to amplify neuromuscular resilience, ultimately enhancing quality of life for this vulnerable cohort.

(Word count: 672)